Y-Intercept (HK)’s Charles River Laboratories CRL Stock Holding History

Y-Intercept (HK)’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$282K	Sell	1,245 -4,669	-79%	-$831K	0.01%	1484
2026 Q1	$1.02M	Sell	5,914 -3,454	-37%	-$640K	0.02%	1021
2025 Q4	$1.87M	Buy	9,368 +1,842	+24%	+$334K	0.04%	657
2025 Q3	$1.18M	Buy	+7,526	New	+$1.2M	0.03%	900
2025 Q2	–	Sell	-3,760	Closed	-$566K	–	1686
2025 Q1	$566K	Buy	+3,760	New	+$630K	0.04%	645
2023 Q3	–	Sell	-10,712	Closed	-$2.25M	–	1136
2023 Q2	$2.25M	Buy	10,712 +8,293	+343%	+$1.65M	0.24%	94
2023 Q1	$488K	Buy	+2,419	New	+$548K	0.06%	544
2022 Q3	–	Sell	-5,558	Closed	-$1.19M	–	1017
2022 Q2	$1.19M	Buy	5,558 +4,727	+569%	+$1.16M	0.16%	187
2022 Q1	$236K	Buy	+831	New	+$256K	0.05%	547

Other funds holding CRL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Y-Intercept (HK)'s CRL Position: Q2 2026 in Review

Y-Intercept (HK) reduced its Charles River Laboratories (CRL) stake by 79% in Q2 2026, selling an estimated $831K and leaving 1,245 shares worth $282K. The position accounts for 0.01% of the portfolio, ranked #1484.

Y-Intercept (HK) first reported a position in CRL in Q1 2022 and has held it in 9 quarters since. The position peaked at $2.25M in Q2 2023. 570 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

Y-Intercept (HK) held 1,245 shares of Charles River Laboratories worth $282K as of Q2 2026.
Y-Intercept (HK) sold 4,669 Charles River Laboratories shares in Q2 2026, an estimated $831K.
Charles River Laboratories made up 0.01% of Y-Intercept (HK)'s portfolio in Q2 2026, its #1484 holding.
Y-Intercept (HK) first reported a position in Charles River Laboratories in Q1 2022 and has held it in 9 quarters since.
Y-Intercept (HK)'s Charles River Laboratories position peaked at $2.25M in Q2 2023.
570 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Y-Intercept (HK)'s 13F filing for Q2 2026, filed 14 Jul 2026.